Astrea Bioseparations (Astrea Bio), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced the launch of its Nereus LentiHero lentiviral vector (LVV) purification technology. Incorporating AstreAdept, the company’s proprietary nanofibre material, this novel solution addresses the challenges associated with purifying the large and fragile products used in cell and gene therapy.
“We believe that AstreAdept will be a game-changer,” explained Astrea Bio’s CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHero a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].” He added, “This launch also sets the stage for a future where cutting-edge therapies can make it into the hands of patients faster and more affordably than ever.”
Despite the significant potential of LVV therapeutics, speed of development has been slow due to the lack of fit-for-purpose platforms, with users dependent on outdated and inefficient devices. To overcome these barriers, Astrea Bio is developing products that are easier to use than previous approaches. “High yield, combined with rapid purification are now possible by using AstreAdept,” explained Pizzie.
AstreAdept is a proprietary bioseparations material that uses cutting-edge nanofibre technology that enables biologics manufacturers to reduce process times, increase process efficiency, reduce buffer consumption, and consequently improve waste treatment costs. As a result, greener, faster, and more cost-effective bioprocessing workflows are possible.
